What is Cellbyte?
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte operates as an AI-native platform specifically engineered for the pharmaceutical industry. The company addresses the significant friction points inherent in global drug launches, including pricing strategies, market access hurdles, and complex regulatory requirements. By automating data extraction and providing actionable insights, Cellbyte enables pharmaceutical organizations to make faster, more informed decisions. Headquartered in Munich, Germany, the company is rapidly establishing itself as a critical partner for enterprises looking to modernize their commercial operations and improve efficiency across international markets.
How much funding has Cellbyte raised?
Cellbyte has raised a total of $2.8M across 1 funding round:
Seed
$2.8M
Seed (2025): $2.8M with participation from Y Combinator, Saras Capital, Pace Ventures, and Frontline Ventures
Key Investors in Cellbyte
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
Saras Capital
Saras Capital LLP is an appointed representative of Midmar Capital LLP, authorized and regulated by the Financial Conduct Authority for UK investment advisory and arranging activities.
Pace Ventures
Pace Ventures is an investment firm focused on the intersection of climate and health, supporting early-stage companies with initial investments ranging from $500,000 to $1.5 million.
What's next for Cellbyte?
With this major enterprise-level funding, Cellbyte is poised to enter a phase of aggressive growth and product development. The strategic roadmap likely includes the expansion of its engineering and sales teams to support a broader client base across Europe and North America. Furthermore, the company is expected to deepen its AI capabilities, potentially integrating more advanced predictive analytics to further optimize drug launch timelines. As the pharmaceutical sector continues to prioritize digital transformation, Cellbyte's role as an operating system for commercial teams will be pivotal in navigating the increasingly complex global regulatory landscape. The firm's ability to maintain its momentum will depend on its success in scaling its platform while ensuring the high level of data integrity required by its enterprise-level pharmaceutical partners.
See full Cellbyte company page
